Revenue + Forward P/E
Teva Pharmaceutical Industries Limited (TEVA) quarterly revenue and forward P/EForward P/E: 13.1x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$43.00B
Enterprise value
$53.22B
P/E ratio (TTM)
53.79x
P/S ratio (TTM)
2.31x
P/B ratio
5.17x
EV/Sales
3.07x
EV/EBITDA
17.40x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$17.26B
Gross profit (TTM)
$8.94B
Operating income (TTM)
$2.16B
EBITDA (TTM)
$3.14B
Net income (TTM)
$1.41B
Free cash flow (TTM)
$1.15B
Margins & returns
Gross margin
52.41%
Operating margin
17.20%
Profit margin
4.18%
Return on equity
9.28%
Return on assets
1.83%
Per-share metrics
EPS (TTM)
$0.62
Dividend yield
0.00%
Beta
0.86
Capital structure
Cash & equivalents
$3.56B
Total debt
$17.38B
Net debt
$13.83B
Shares outstanding
1.16B
Financial health
Current ratio
1.04
Debt / equity
2.20
Debt / assets
0.43
Interest coverage
2.35
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $630.04B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.72B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.28B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $355.30B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.73B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $43.00B | 53.79x | 2.31x | 17.40x | - |